

Resource Summary Report

Generated by [NIF](#) on Sep 13, 2026

SNU-398

RRID:CVCL_0077

Type: Cell Line

Proper Citation

RRID:CVCL_0077

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0077

Proper Citation: RRID:CVCL_0077

Description: Cell line SNU-398 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Adult hepatocellular carcinoma

Defining Citation: [PMID:7543080](#), [PMID:8824565](#), [PMID:19956504](#), [PMID:20215515](#), [PMID:22460905](#), [PMID:23505090](#), [PMID:23887712](#), [PMID:25485619](#), [PMID:25574106](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:30894373](#), [PMID:31063779](#), [PMID:31068700](#), [PMID:31378681](#), [PMID:35839778](#)

Comments: Karyotypic information: Has lost chromosome Y., Population: Korean., Part of: Seoul National University (SNU) cell line collection., Part of: MD Anderson Cell Lines Project., Part of: Liver Cancer Model Repository (LIMORE)., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: SNU-398

Synonyms: SNU398, NCI-SNU-398

Cross References: BTO:BTO_0003170, CLO:CLO_0009098, EFO:EFO_0002347, MCCL:MCC:0000435, ArrayExpress:E-MTAB-38, ArrayExpress:E-MTAB-2706, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ATCC:CRL-2233, BioGRID_ORCS_Cell_line:368, BioSample:SAMN03473191, BioSample:SAMN10987942,

cancercelllines:CVCL_0077, Cell_Model_Passport:SIDM01181, ChEMBL-Cells:ChEMBL3307619, ChEMBL-Targets:ChEMBL614454, CLS:305274, Cosmic:873393, Cosmic:928143, Cosmic:1187337, Cosmic:1995640, Cosmic:2009538, Cosmic:2023868, Cosmic:2162531, Cosmic:2321036, Cosmic:2771606, Cosmic-CLP:1240217, DepMap:ACH-000221, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:1240217, GEO:GSM481448, GEO:GSM565922, GEO:GSM827415, GEO:GSM887623, GEO:GSM888708, GEO:GSM936780, GEO:GSM1374890, GEO:GSM1670468, GEO:GSM2551587, IARC_TP53:6307, IGRhCellID:SNU398, KCLB:00398, LiGeA:CCLE_422, LIMORE:SNU398, LINCS_LDP:LCL-1934, PharmacoDB:SNU398_1458_2019, PRIDE:PXD030304, Progenetix:CVCL_0077, PubChem_Cell_line:CVCL_0077, Wikidata:Q54955184

ID: CVCL_0077

Record Creation Time: 20220427T221552+0000

Record Last Update: 20260913T010057+0000

Ratings and Alerts

No rating or validation information has been found for SNU-398.

No alerts have been found for SNU-398.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 27 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Zheleznyak A, et al. (2026) Epithelial-Mesenchymal Transition and Stress Adaptations Underlie Yttrium-90 Resistance in Liver Cancer Cell Lines. Cancer research communications, 6(1), 178.

Hacioglu N, et al. (2026) Hypoxia-driven transcriptional activation of MIR100HG by HIF-1? contributes to adaptive gene regulation in hepatocellular carcinoma. Functional & integrative genomics, 26(1).

Jang SH, et al. (2026) Epigenetic silencing of the liver-specific lncRNA LUNAR promotes liver cancer progression via NOTCH activation. Molecular oncology.

Dzama-Karels M, et al. (2025) Menin-MLL1 complex cooperates with NF-Y to promote hepatocellular carcinoma survival. Cell reports, 44(12), 116619.

Turnham RE, et al. (2025) HBV Remodels PP2A Complexes to Rewire Kinase Signaling in Hepatocellular Carcinoma. Cancer research, 85(4), 660.

Hu Y, et al. (2025) Targeting PRDX6-dependent localization and function of GPX4 enhances ferroptosis-mediated tumor suppression. *Molecular cell*, 85(24), 4602.

Mesropian A, et al. (2025) E7386 Enhances Lenvatinib's Antitumor Activity in Preclinical Models and Human Hepatocellular Carcinoma. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(23), 5037.

Luo C, et al. (2025) Integrated computational analysis identifies therapeutic targets with dual action in cancer cells and T cells. *Immunity*, 58(3), 745.

Yoon SJ, et al. (2023) Comprehensive Metabolic Tracing Reveals the Origin and Catabolism of Cysteine in Mammalian Tissues and Tumors. *Cancer research*, 83(9), 1426.

Koval A, et al. (2023) Improved approaches to channel capacity estimation discover compromised GPCR signaling in diverse cancer cells. *iScience*, 26(8), 107270.

Azbazdar Y, et al. (2023) Comparative membrane lipidomics of hepatocellular carcinoma cells reveals diacylglycerol and ceramide as key regulators of Wnt/ β -catenin signaling and tumor growth. *Molecular oncology*, 17(11), 2314.

Sanchez-Moral L, et al. (2023) Macrophage CD5L is a target for cancer immunotherapy. *EBioMedicine*, 91, 104555.

Uong TNT, et al. (2023) Direct Tumor Irradiation Potentiates Adoptive NK Cell Targeting Against Parental and Stemlike Cancer in Human Liver Cancer Models. *International journal of radiation oncology, biology, physics*.

Thng DKH, et al. (2023) Histone-lysine N-methyltransferase EHMT2 (G9a) inhibition mitigates tumorigenicity in Myc-driven liver cancer. *Molecular oncology*.

Zheng G, et al. (2022) Integrin alpha 6 is upregulated and drives hepatocellular carcinoma progression through integrin α 6 β 4 complex. *International journal of cancer*, 151(6), 930.

Missiaen R, et al. (2022) GCN2 inhibition sensitizes arginine-deprived hepatocellular carcinoma cells to senolytic treatment. *Cell metabolism*, 34(8), 1151.

Yang C, et al. (2022) A survey of optimal strategy for signature-based drug repositioning and an application to liver cancer. *eLife*, 11.

Stribbling SM, et al. (2022) The cell-line-derived subcutaneous tumor model in preclinical cancer research. *Nature protocols*, 17(9), 2108.

Kong NR, et al. (2021) Zinc Finger Protein SALL4 Functions through an AT-Rich Motif to Regulate Gene Expression. *Cell reports*, 34(1), 108574.

Okuda K, et al. (2021) Enhanced Antitumor Effect in Liver Cancer by Amino Acid Depletion-Induced Oxidative Stress. *Frontiers in oncology*, 11, 758549.